Table 12.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1996 to 2005

Recipients with Lung Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 837 948 893 922 977 1,083 1,054 1,099 1,185 1,407
Tx with Follow-up Immunosuppression Info 565 671 627 664 735 804 827 879 981 1,116
Corticosteroids Any in Category 99.3% 98.2% 99.5% 99.1% 98.6% 99.5% 97.0% 97.8% 99.3% 99.2%
Steroids 99.3% 98.2% 99.5% 99.1% 98.6% 99.5% 97.0% 97.8% 99.3% 99.2%
Cyclosporine Any in Category 69.7% 62.0% 64.0% 63.7% 54.6% 45.9% 35.3% 30.8% 24.5% 22.9%
Cyclosporin 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.1% 0.0% 0.1% 0.5%
Sandimmmune 14.0% 8.0% 6.5% 4.7% 4.2% 5.0% 2.5% 2.6% 1.2% 1.6%
Neoral 55.6% 53.8% 57.4% 58.6% 48.2% 34.0% 26.0% 20.8% 17.5% 15.1%
Gengraf 0.0% 0.1% 0.0% 0.3% 1.9% 6.3% 6.5% 7.2% 5.6% 5.5%
Eon 0.2% 0.0% 0.0% 0.2% 0.0% 0.1% 0.1% 0.2% 0.0% 0.3%
Tacrolimus Any in Category 33.6% 37.7% 41.9% 46.5% 55.6% 69.2% 75.7% 76.2% 83.6% 85.9%
Tacrolimus 33.6% 37.7% 41.9% 46.5% 55.6% 69.2% 75.7% 76.2% 83.6% 85.9%
Antimetabolites Any in Category 88.7% 88.5% 93.0% 91.4% 94.3% 90.8% 88.8% 87.9% 88.7% 91.7%
Mycophenolate Mofetil 19.8% 30.4% 30.3% 33.9% 40.8% 42.3% 45.1% 46.6% 49.1% 51.9%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 3.4%
Azathioprine 68.5% 57.5% 62.5% 57.5% 53.3% 48.1% 43.7% 41.3% 39.3% 36.2%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.2%
Cytoxan 0.4% 0.6% 0.2% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0%
mTOR Inhibitors Any in Category 0.0% 0.0% 0.3% 6.2% 6.3% 11.1% 14.4% 10.1% 8.6% 7.9%
Sirolimus 0.0% 0.0% 0.2% 5.9% 6.3% 11.1% 14.4% 10.1% 8.6% 7.9%
Everolimus 0.0% 0.0% 0.2% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.